Evercore ISI analyst Ross Muken maintained a Buy rating on Quest Diagnostics Inc (DGX) yesterday and set a price target of $108. The company’s shares opened today at $100.22.
Muken said:
“We spent time on the west coast last week (LA + SF weather right now >>> Diagnostics (CFO and IR). Post solid 1H results after a reset in sentiment, numbers, and multiples last year, it is safe to say investor perception has recovered somewhat and the focus has shifted back towards the longer term path with the possibility of regulatory easing (particularly as organic volumes surprised last Q).”
According to TipRanks.com, Muken is a 5-star analyst with an average return of 19.6% and a 74.2% success rate. Muken covers the Services sector, focusing on stocks such as Cardinal Health, Laboratory Corp, and CVS Health.
Currently, the analyst consensus on Quest Diagnostics Inc is a Hold with an average price target of $105.63, which is a 5.4% upside from current levels. In a report issued on July 23, Canaccord Genuity also maintained a Buy rating on the stock with a $112 price target.
See today’s analyst top recommended stocks >>
Quest Diagnostics Inc’s market cap is currently $13.46B and has a P/E ratio of 18.83. The company has a Price to Book ratio of 2.47.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. Most recently, in June 2019, Stephen Rusckowski, the COB, Pres & CEO of DGX sold 244,565 shares for a total of $24,456,500.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers.
